Jane Street’s Kyverna Therapeutics KYTX Stock Holding History

Jane Street’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$899K	Sell	104,214 -77,879	-43%	-$649K	﹤0.01%	6745
2025 Q4	$1.71M	Sell	182,093 -16,758	-8%	-$124K	﹤0.01%	5104
2025 Q3	$1.19M	Buy	198,851 +111,082	+127%	+$444K	﹤0.01%	5929
2025 Q2	$269K	Buy	+87,769	New	+$217K	﹤0.01%	8049
2024 Q4	–	Sell	-39,193	Closed	-$192K	–	10791
2024 Q3	$192K	Buy	39,193 +17,215	+78%	+$133K	﹤0.01%	8675
2024 Q2	$165K	Sell	21,978 -15,063	-41%	-$230K	﹤0.01%	8524
2024 Q1	$920K	Buy	+37,041	New	+$1.03M	﹤0.01%	5569

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Jane Street's KYTX Position: Q1 2026 in Review

Jane Street reduced its Kyverna Therapeutics (KYTX) stake by 43% in Q1 2026, selling an estimated $649K and leaving 104,214 shares worth $899K. The position accounts for ﹤0.01% of the portfolio, ranked #6745.

Jane Street first reported a position in KYTX in Q1 2024 and has held it in 7 quarters since. The position peaked at $1.71M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

Jane Street held 104,214 shares of Kyverna Therapeutics worth $899K as of Q1 2026.
Jane Street sold 77,879 Kyverna Therapeutics shares in Q1 2026, an estimated $649K.
Kyverna Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6745 holding.
Jane Street first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 7 quarters since.
Jane Street's Kyverna Therapeutics position peaked at $1.71M in Q4 2025.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.